{"id":1018180,"date":"2026-11-06T00:24:09","date_gmt":"2026-11-06T05:24:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-pacira-biosciences-inc-pcrx\/"},"modified":"2026-11-06T00:24:09","modified_gmt":"2026-11-06T05:24:09","slug":"pacira-biosciences-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-pacira-biosciences-inc-pcrx","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-pacira-biosciences-inc-pcrx\/","title":{"rendered":"Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. – PCRX"},"content":{"rendered":"

<\/p>\n

Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. – PCRX<\/p>\n

NEW YORK & NEW ORLEANS–(BUSINESS WIRE<\/a>)–Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti<\/a>, LLC (\u201cKSF\u201d) are investigating the proposed sale of Pacira BioSciences<\/a>, Inc. (NasdaqGS: PCRX) to Viatris Inc. (NasdaqGS: VTRS). Under the terms of the proposed transaction, shareholders of Pacira will receive $36.50 in cash for each share of Pacira that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.<\/p>\n

If you believe that this transaction undervalues the Company and\/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com<\/a>) toll free at any time at (833) 538-3612, or visit https:\/\/www.ksfcounsel.com\/cases\/nasdaqgs-pcrx\/<\/a> to learn more.<\/p>\n

Please note that the transaction is structured as a tender offer, such that time may be of the essence.<\/i><\/strong><\/p>\n

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com<\/a>.<\/p>\n

CONNECT WITH US: Facebook<\/a> || Instagram<\/a> || YouTube<\/a> || TikTok<\/a> || LinkedIn<\/a><\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20261105961378\/en\/<\/a><\/span><\/p>\n

Kahn Swick & Foti, LLC
KSF Managing Partner
Lewis S. Kahn
lewis.kahn@ksfcounsel.com<\/a>
(833) 538-3612<\/p>\n

KEYWORDS:<\/b> United States North America Louisiana New York<\/p>\n

INDUSTRY KEYWORDS:<\/b> Class Action Lawsuit Professional Services Legal<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. – PCRX NEW YORK & NEW ORLEANS–(BUSINESS WIRE)–Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (\u201cKSF\u201d) are investigating the proposed sale of Pacira BioSciences, Inc. (NasdaqGS: PCRX) to Viatris Inc. (NasdaqGS: VTRS). Under the terms of the proposed transaction, shareholders of Pacira will receive $36.50 in cash for each share of Pacira that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues … <\/p>\n

Continue reading “Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. – PCRX”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1018180","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nPacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-pacira-biosciences-inc-pcrx\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. – PCRX NEW YORK & NEW ORLEANS–(BUSINESS WIRE)–Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (\u201cKSF\u201d) are investigating the proposed sale of Pacira BioSciences, Inc. (NasdaqGS: PCRX) to Viatris Inc. (NasdaqGS: VTRS). Under the terms of the proposed transaction, shareholders of Pacira will receive $36.50 in cash for each share of Pacira that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues … Continue reading "Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. – PCRX"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-pacira-biosciences-inc-pcrx\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-06T05:24:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20261105961378r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-pacira-biosciences-inc-pcrx\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-pacira-biosciences-inc-pcrx\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. – PCRX\",\"datePublished\":\"2026-11-06T05:24:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-pacira-biosciences-inc-pcrx\\\/\"},\"wordCount\":290,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-pacira-biosciences-inc-pcrx\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20261105961378r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-pacira-biosciences-inc-pcrx\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-pacira-biosciences-inc-pcrx\\\/\",\"name\":\"Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-pacira-biosciences-inc-pcrx\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-pacira-biosciences-inc-pcrx\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20261105961378r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2026-11-06T05:24:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-pacira-biosciences-inc-pcrx\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-pacira-biosciences-inc-pcrx\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-pacira-biosciences-inc-pcrx\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20261105961378r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20261105961378r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-pacira-biosciences-inc-pcrx\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. – PCRX\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-pacira-biosciences-inc-pcrx\/","og_locale":"en_US","og_type":"article","og_title":"Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX - Market Newsdesk","og_description":"Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. – PCRX NEW YORK & NEW ORLEANS–(BUSINESS WIRE)–Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (\u201cKSF\u201d) are investigating the proposed sale of Pacira BioSciences, Inc. (NasdaqGS: PCRX) to Viatris Inc. (NasdaqGS: VTRS). Under the terms of the proposed transaction, shareholders of Pacira will receive $36.50 in cash for each share of Pacira that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues … Continue reading \"Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. – PCRX\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-pacira-biosciences-inc-pcrx\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-06T05:24:09+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20261105961378r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-pacira-biosciences-inc-pcrx\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-pacira-biosciences-inc-pcrx\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. – PCRX","datePublished":"2026-11-06T05:24:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-pacira-biosciences-inc-pcrx\/"},"wordCount":290,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-pacira-biosciences-inc-pcrx\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20261105961378r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-pacira-biosciences-inc-pcrx\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-pacira-biosciences-inc-pcrx\/","name":"Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-pacira-biosciences-inc-pcrx\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-pacira-biosciences-inc-pcrx\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20261105961378r1&sid=flmnd&distro=nx&lang=en","datePublished":"2026-11-06T05:24:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-pacira-biosciences-inc-pcrx\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-pacira-biosciences-inc-pcrx\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-pacira-biosciences-inc-pcrx\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20261105961378r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20261105961378r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-pacira-biosciences-inc-pcrx\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. – PCRX"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1018180","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1018180"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1018180\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1018180"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1018180"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1018180"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}